Prince Pharmaceutical Co., Ltd. (TPEX:6935)
Taiwan · Delayed Price · Currency is TWD 29.30
+0.55 (1.91%)
At close: Feb 11, 2026
Prince Pharmaceutical Revenue
Prince Pharmaceutical had revenue of 448.06M TWD in the half year ending June 30, 2025, with 25.86% growth. This brings the company's revenue in the last twelve months to 798.27M, up 8.29% year-over-year. In the year 2024, Prince Pharmaceutical had annual revenue of 690.03M, down -8.40%.
Revenue (ttm)
798.27M
Revenue Growth
+8.29%
P/S Ratio
1.34
Revenue / Employee
3.80M
Employees
210
Market Cap
1.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 690.03M | -63.30M | -8.40% |
| Dec 31, 2023 | 753.33M | 40.80M | 5.73% |
| Dec 31, 2022 | 712.53M | 271.45M | 61.54% |
| Dec 31, 2021 | 441.08M | 145.28M | 49.12% |
| Dec 31, 2020 | 295.79M | 46.19M | 18.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Excelsior Biopharma | 898.26M |
| Anxo Pharmaceutical | 883.22M |
| Winston Medical Supply | 724.35M |
| DV Biomed | 712.61M |
| GeneFerm Biotechnology | 654.88M |
| Tien Liang BioTech | 467.02M |
| General Biologicals | 251.38M |
| Mediera | 240.30M |